Business
Press Release Jun 04 2021
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 04, 2021, titled "Glenmark Pharmaceuticals receives ANDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg:Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity on the 450 mg".
About this update from Glenmark Pharmaceuticals Limited
[{"type":"text","content":" Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 04, 2021, titled \"Glenmark Pharmaceuticals receives ANDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg:Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity on the 450 mg\". View Attachment","length":491,"tagName":"div"}]